You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
加科思(01167.HK)回升13%成交增 自主研发新药获国家药监局准临床实验
阿思达克 05-28 10:32
加科思-B(01167.HK)自主研发新药获国家药监局批准进行临床实验,该股整固守稳20天线,今早曾急涨16%至24.25元,现造23.55元,急涨13%,一向薄弱成交增至111万股,涉资2,594万元。

加科思公布,公司自主研发的JAB-21822项目KRAS G12C抑制剂的新药临床试验申请已於5月27日获得国家药品监督管理局药品审评中心批准,此前该项目IND已获得美国FDA批准。该新药将用於治疗KRAS G12C突变的晚期实体瘤,包括但不限於非小细胞肺癌(NSCLC)及结直肠癌(CRC)等晚期实体瘤。

加科思是一家仍处於临床阶段制药公司,专注於创新肿瘤疗法自主研发。股份於去年12月中旬以每股14元在港上市,净筹12.63亿元,主要用作产品的临床开发和商业化。挂牌後,股价曾於上市首周反覆低见13元获承接回升,并於今年2月初曾升至25.35元上市新高。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account